Ignite Creation Date:
2024-05-06 @ 2:40 PM
Last Modification Date:
2024-10-26 @ 1:34 PM
Study NCT ID:
NCT04382768
Status:
UNKNOWN
Last Update Posted:
2020-06-11
First Post:
2020-05-06
Brief Title:
Inhaled Ibuprofen to Treat COVID-19
Sponsor:
Química Luar SRL
Organization:
Química Luar SRL
Study Overview
Official Title:
Extended Compassionate Use Program UCA With Inhalational Ibuprofen in Patients With Acute Respiratory Pathology Mediated by COVID-19
Status:
UNKNOWN
Status Verified Date:
2020-06
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CórdobaTrail
Brief Summary:
The study aims to evaluate the reduction in severity and progression of lung injury with inhaled ibuprofen in patients with severe acute respiratory syndrome due to SARS-CoV-2 virus
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None